The role of PD-L2 within the PD-1-driven axis in NSCLC: From molecular mechanisms to clinical translation
Therapeutic Advances in Medical Oncology · 2026-11 · 18
DOI: 10.1177/17588359261504790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 12.11.2026. Verfasst von Federico Pio Fabrizio und 4 weiteren Autor:innen. Die Arbeit nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The PD-1 (Programmed Death-1)/PD-L1 (Programmed Death-Ligand 1)/PD-L2 (Programmed Death-Ligand 2) axis underlies inhibitory signaling in the regulatory mechanisms of antitumor immunity in non-small cell lung cancer (NSCLC). Although PD-L1 is widely recognized as a predictive biomarker for PD-1/PD-L1 blockade, the molecular, histopathological, and regulatory characterization of PD-L2, as well as its potential clinical associations, remain to be defined. To date, the available evidence suggests that PD-L2 expression in NSCLC may be linked to a complex network involving diverse mechanisms, ranging from genetic and epigenetic factors to transcriptional, post-transcriptional mechanisms, all sharing a common denominator: the dysregulation of inflammatory and oncogenic signals underlying specific pathways that shape heterogeneous expression within and across different tumor subtypes. From an immunological perspective, PD-L2 has been implicated in the regulation of tumor immune evasion mechanisms by modulating T-cell activation and may contribute to an immunosuppressive state within the lung tumor microenvironment (TME), where various types of immune and stromal cell populations coexist and interact, including dendritic cells, fibroblasts, macrophages, and T cells. To date, molecular and histopathological studies have not yet fully clarified the role of PD-L2, but they point to a scenario in which the expression, distribution, and histopathological localization of this target are potentially distinct from those of PD-L1. Several underlying factors contribute to this variability, as well as heterogeneity of tumor phenotypes, differences in composition of cellular components within TME, the associated clinical characteristics that distinguish different subgroups of NSCLC patients and their responses to immuno-therapies. PD-L2 expression can also be found in PD-L1-negative NSCLC tumors, raising the hypothesis that it might contribute to patient stratification in the setting of immune checkpoint inhibition. However, current clinical evidence is very limited and does not establish a predictive role for PD-L2. This narrative review summarizes the current molecular, histo-pathological, and functional understanding of PD-L2 regulation across different NSCLC histologies, integrating emerging clinical data to address an unmet clinical need and provide a more up-to-date perspective that links biological mechanisms to increasingly relevant translational implications.
Zitieren
APA
Fabrizio, F. P., Bravaccini, S., Angelico, G., Torrisi, F., & Rossi, A. (2026). The role of PD-L2 within the PD-1-driven axis in NSCLC: From molecular mechanisms to clinical translation. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261504790
Vancouver
Fabrizio FP, Bravaccini S, Angelico G, Torrisi F, Rossi A. The role of PD-L2 within the PD-1-driven axis in NSCLC: From molecular mechanisms to clinical translation. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261504790
BibTeX
@article{Fabrizio2026,
author = {Fabrizio, Federico Pio and Bravaccini, Sara and Angelico, Giuseppe and Torrisi, Filippo and Rossi, Antonio},
title = {The role of PD-L2 within the PD-1-driven axis in NSCLC: From molecular mechanisms to clinical translation},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261504790}
}
EUVIMED